At the 8th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress 2017 recently held in Kuala Lumpur, consultant endocrinologist Professor Siew-Pheng Chan spoke on the importance of lipid control in patients with type 2 diabetes mellitus (T2DM) with atherogenic dyslipidaemia (AD), highlighting the role of fenofibrate in the management of diabetic retinopathy.
Available in Europe since 1978, trimetazidine was launched in Malaysia in 1986 as VASTAREL® 20, with the first box of this medication sold in 1987. At that time, this agent was available as three times daily dosing; this was soon followed by the modified-release formulation, ie, VASTAREL® MR®, launched in 2005 to simplify the dosing regimen. By 2007, VASTAREL® MR® had become widely available in public hospitals throughout Malaysia.The efficacy of trimetazidine in coronary artery disease (CAD) is well established – it is a well-tolerated anti-ischaemic agent with no effect on blood pressure or heart rate. It is also recommended by Malaysian and international guidelines for symptomatic relief of angina. In conjunction with the 30th anniversary of VASTAREL®, renowned local and international opinion leaders gathered at a Servier symposium, chaired by Dr Jeyamalar Rajadurai, to reflect on the evolution of CAD management and the contemporary role of trimetazidine.
Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 20170831100001
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
Prof. Peter Collins, Prof. Giuseppe Mancia, Prof. Carolyn Lam, Dr. Choo Gim Hooi, 20170712103633
Coronary artery disease (CAD) is the leading cause of death worldwide
and is expected to remain so for the foreseeable future due to both the
ageing population and the increasing prevalence of risk factors such as
hypertension, dyslipidaemia, and diabetes. CAD is also the primary risk
factor in the development of heart failure (HF). At the 2nd Asia Pacific
CardioConnect Meeting in Hong Kong sponsored by Menarini, a group of
international and regional experts discussed current strategies for
managing stable CAD and HF and highlighted areas where patient outcomes
may be improved.
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 20161212084416
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
The addition of evolocumab to statin therapy in individuals with angiographic coronary disease appeared to encourage coronary atherosclerosis regression, as demonstrated in the GLAGOV* trial presented at the Scientific Sessions of the American Heart Association (AHA 2016) held in New Orleans, Louisiana, US.